[{"id":"5f6cead8-271a-4f4a-b549-d12536680be3","acronym":"ETCTN","url":"https://clinicaltrials.gov/study/NCT04340843","created_at":"2023-11-13T22:14:48.481Z","updated_at":"2024-07-02T16:35:03.396Z","phase":"Phase 2","brief_title":"Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma","source_id_and_acronym":"NCT04340843 - ETCTN","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":"","alterations":" ","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine) • Beleodaq (belinostat) • guadecitabine (SGI-110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 09/08/2020","start_date":" 09/08/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-05-16"},{"id":"7737d144-a404-4582-aab1-5735a517fdd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03206047","created_at":"2021-01-18T15:48:08.496Z","updated_at":"2024-07-02T16:35:11.758Z","phase":"Phase 1/2","brief_title":"Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03206047","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CTAG1B","pipe":" | ","alterations":" PD-L1 expression • CTAG1B expression","tags":["PD-L1 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Hiltonol (poly-ICLC) • guadecitabine (SGI-110) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 11/08/2017","start_date":" 11/08/2017","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-04-03"},{"id":"241b310b-ed13-4033-b928-505add39916c","acronym":"NCI-2016-00343","url":"https://clinicaltrials.gov/study/NCT02684162","created_at":"2021-01-18T13:05:26.435Z","updated_at":"2024-07-02T16:35:12.965Z","phase":"Phase 2","brief_title":"Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant","source_id_and_acronym":"NCT02684162 - NCI-2016-00343","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e guadecitabine (SGI-110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 06/22/2016","start_date":" 06/22/2016","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-25"},{"id":"a235b506-8835-43df-8263-a23bea27a842","acronym":"HyPeR","url":"https://clinicaltrials.gov/study/NCT02998567","created_at":"2021-01-18T14:45:00.716Z","updated_at":"2025-02-25T16:05:35.405Z","phase":"Phase 1","brief_title":"Combination Study of Guadecitabine/ASTX727 and Pembrolizumab","source_id_and_acronym":"NCT02998567 - HyPeR","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Inqovi (decitabine/cedazuridine) • guadecitabine (SGI-110)"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 01/26/2017","start_date":" 01/26/2017","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-03-20"},{"id":"6b69a04e-98c0-4bfd-b825-c53f82dd8ac3","acronym":"NCI-2016-01233","url":"https://clinicaltrials.gov/study/NCT02935361","created_at":"2024-02-14T01:26:00.848Z","updated_at":"2024-07-02T16:35:19.676Z","phase":"Phase 1/2","brief_title":"Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed","source_id_and_acronym":"NCT02935361 - NCI-2016-01233","lead_sponsor":"University of Southern California","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • guadecitabine (SGI-110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 11/02/2016","start_date":" 11/02/2016","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-02-13"},{"id":"25b49b5c-1205-49a0-873e-9be6de80eb2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03576963","created_at":"2021-01-18T14:26:35.700Z","updated_at":"2025-02-25T14:27:13.292Z","phase":"Phase 1/2","brief_title":"Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03576963","lead_sponsor":"University of Southern California","biomarkers":" PD-L1 • IGF2 • SOCS1 • RUNX3 • NEUROG1","pipe":" | ","alterations":" RAS wild-type","tags":["PD-L1 • IGF2 • SOCS1 • RUNX3 • NEUROG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • guadecitabine (SGI-110)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/30/2020","start_date":" 01/30/2020","primary_txt":" Primary completion: 01/30/2022","primary_completion_date":" 01/30/2022","study_txt":" Completion: 01/30/2023","study_completion_date":" 01/30/2023","last_update_posted":"2021-04-05"},{"id":"6720ec52-70b6-4202-b84d-2f5bc25aa892","acronym":"NIBIT-ML1","url":"https://clinicaltrials.gov/study/NCT04250246","created_at":"2021-01-18T20:39:14.733Z","updated_at":"2025-02-25T14:29:01.090Z","phase":"Phase 2","brief_title":"A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1","source_id_and_acronym":"NCT04250246 - NIBIT-ML1","lead_sponsor":"Italian Network for Tumor Biotherapy Foundation","biomarkers":" BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • ALK translocation","tags":["BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • guadecitabine (SGI-110)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 03/01/2020","start_date":" 03/01/2020","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2020-01-31"},{"id":"da191392-e6f7-4b8c-95c1-bc03652f734d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01752933","created_at":"2021-01-18T07:41:43.278Z","updated_at":"2024-07-02T16:36:51.290Z","phase":"Phase 2","brief_title":"SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)","source_id_and_acronym":"NCT01752933","lead_sponsor":"Astex Pharmaceuticals, Inc.","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • guadecitabine (SGI-110)"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 09/01/2015","primary_completion_date":" 09/01/2015","study_txt":" Completion: 09/01/2015","study_completion_date":" 09/01/2015","last_update_posted":"2020-01-18"},{"id":"c6c47837-bd47-4f85-9210-8886f1881bbc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03085849","created_at":"2021-01-18T15:12:08.278Z","updated_at":"2024-07-02T16:37:04.802Z","phase":"Phase 1","brief_title":"SGI-110 Plus Durvalumab/Tremelimumab in SCLC","source_id_and_acronym":"NCT03085849","lead_sponsor":"Catherine Shu","biomarkers":" PD-L1","pipe":" | ","alterations":" TILs","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • guadecitabine (SGI-110)"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 12/15/2017","start_date":" 12/15/2017","primary_txt":" Primary completion: 11/26/2018","primary_completion_date":" 11/26/2018","study_txt":" Completion: 11/26/2018","study_completion_date":" 11/26/2018","last_update_posted":"2018-12-10"},{"id":"726ad948-1773-436e-835d-7cfe52ad8491","acronym":"","url":"https://clinicaltrials.gov/study/NCT03454984","created_at":"2021-01-18T17:02:07.882Z","updated_at":"2024-07-02T16:37:05.317Z","phase":"Phase 2","brief_title":"SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation","source_id_and_acronym":"NCT03454984","lead_sponsor":"Groupe Francophone des Myelodysplasies","biomarkers":" TP53","pipe":"","alterations":" ","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e guadecitabine (SGI-110)"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 09/01/2020","primary_completion_date":" 09/01/2020","study_txt":" Completion: 03/01/2022","study_completion_date":" 03/01/2022","last_update_posted":"2018-11-15"}]